Coagulopathy and extremely elevated PT/INR after dabigatran etexilate use in a patient with end-stage renal disease

Case Reports in Medicine

Volumn 2013, Issue , 2013, Pages

  Kim, Joonseok ^a   Yadava, Mrinal ^a   An, In Chul ^a   Sayeed, Abrar ^a   Laird Fick, Heather S ^a   Gourineni, Venu ^a   Abela, George S ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942903794     PISSN: 16879627     EISSN: 16879635     Source Type: Journal    
DOI: 10.1155/2013/131395     Document Type: Article

References (21)

1. Kirley K., Qato D. M., Kornfield R., Stafford R. S., Alexander G. C., National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012 5 615 621
2. Gage B. F., Van Walraven C., Pearce L., Hart R. G., Koudstaal P. J., Boode B. S. P., Petersen P., Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004 110 16 2287 2292 2-s2.0-6444240752 10.1161/01.CIR.0000145172. 55640.93 (Pubitemid 39407328)
3. Chen B. C., Sheth N. R., Dadzie K. A., Smith S. W., Nelson L. S., Hoffman R. S., Winchester J. F., Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. American Journal of Kidney Diseases 2013 62 3 591 594 10.1053/j.ajkd.2013.02.361
4. Fountzilas C., George J., Levine R., Dabigatran overdose secondary to acute kidney injury and amiodarone use. The New Zealand Medical Journal 2013 126 110 112
5. Lal Y., Van Heukelom J., Dabigatran: a cause of hematologic emergency. The American Journal of the Medical Sciences 2012 364 3 190 193 10.1097/MAJ.0b013e31826c5a56
6. Chang D. N., Dager W. E., Chin A. I., Removal of dabigatran by hemodialysis. American Journal of Kidney Diseases 2013 61 487 489
7. Maddry J. K., Amir M. K., Sessions D., Heard K., Fatal dabigatran toxicity secondary to acute renal failure. American Journal of Emergency Medicine 2013 31 2 462.e1 462.e2 10.1016/j.ajem.2012.08.015
8. Hughes B., First oral warfarin alternative approved in the US. Nature Reviews Drug Discovery 2010 9 12 903 906 2-s2.0-78649717192 10.1038/nrd3322
9. Schulman S., Majeed A., The oral thrombin inhibitor dabigatran: strengths and weaknesses. Seminars in Thrombosis and Hemostasis 2012 38 1 7 15 2-s2.0-84857015242 10.1055/s-0031-1300946
10. Stangier J., Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clinical Pharmacokinetics 2008 47 5 285 295 2-s2.0-41949116970 10.2165/00003088-200847050-00001 (Pubitemid 351508116)
11. Stangier J., Rathgen K., Stähle H., Gansser D., Roth W., The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. British Journal of Clinical Pharmacology 2007 64 3 292 303 2-s2.0-34548031359 10.1111/j.1365-2125. 2007.02899.x (Pubitemid 47283865)
12. Eikelboom J. W., Wallentin L., Connolly S. J., Ezekowitz M., Healey J. S., Oldgren J., Yang S., Alings M., Kaatz S., Hohnloser S. H., Diener H.-C., Franzosi M. G., Huber K., Reilly P., Varrone J., Yusuf S., Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial. Circulation 2011 123 21 2363 2372 2-s2.0-79958126202 10.1161/CIRCULATIONAHA.110.004747
13. FDA drug safety communication: update on the risk for serious bleeding events with the anticoagulant Pradaxa. 2012
14. van Ryn J., Litzenburger T., Waterman K., Canada K., Hauel N., Sarko C., Kroe-Barrett R., Singh S., Park J., Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran. Proceedings of the American College of Cardiologists Annual Conference
15. FDA Monitoring MedWatch Reports, Anticoagulants the Leading Reported Drug Risk in 2011 May 31, 2012. New Data from 2011 Quarters 3-4, 2012
16. Van Ryn J., Stangier J., Haertter S., Liesenfeld K.-H., Wienen W., Feuring M., Clemens A., Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and Haemostasis 2010 103 6 1116 1127 2-s2.0-77953168824 10.1160/TH09-11-0758
17. Harenberg J., Giese C., Marx S., Krämer R., Determination of dabigatran in human plasma samples. Seminars in Thrombosis and Hemostasis 2012 38 1 16 22 2-s2.0-84857014060 10.1055/s-0031-1300947
18. Heidbuchel H., Verhamme P., Alings M., Antz M., Hacke W., Oldgren J., Sinnaeve P., Camm A. J., Kirchhof P., EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. European Heart Journal 2013 10.1093/eurheartj/eht134
19. Van Ryn J., Baruch L., Clemens A., Interpretation of point-of-care INR results in patients treated with dabigatran. American Journal of Medicine 2012 125 4 417 420 2-s2.0-84858966373 10.1016/j.amjmed.2011.10.017
20. Kernan L., Ito S., Shirazi F., Boesen K., Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clinical Toxicology 2012 50 571 573
21. Lindahl T. L., Baghaei F., Blixter I. F., Gustafsson K. M., Stigendal L., Sten-Linder M., Strandberg K., Hillarp A., Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thrombosis and Haemostasis 2011 105 2 371 378 2-s2.0-79851482951 10.1160/TH10-06-0342